Literature DB >> 20694275

Haemophilia, human immunodeficiency virus and human immunodeficiency virus pathogenesis.

Michael M Lederman1.   

Abstract

In July 1982, the occurrence of three cases of acquired immunodeficiency syndrome (AIDS) in men with haemophilia was an immediate signal to Oscar Ratnoff that AIDS was transmissible through blood products. Work that he led provided important and clear indication that the AIDS agent was transmissible through pooled plasma products and had rapidly infected many men who had haemophilia. Before the blood supply was protected, the risk for infection in haemophilia was related directly to the intensity of therapy with pooled anti-haemophilic factor concentrates. Studies performed among the small proportion of haemophiliacs who remained uninfected despite heavy exposure to these plasma products revealed that the rare protective genotype - homozygosity for the 32 base pair deletion in the CCR5 gene was heavily concentrated in this population. Among those who did not have this protective genotype, a state of diminished immune activation distinguished these high risk uninfected haemophiliacs from haemophiliacs who later acquired human immunodeficiency virus (HIV) infection and from healthy uninfected controls. Immune activation state may not only predict risk for HIV acquisition but also appears to be an important predictor and likely determinant of HIV disease progression. The potential drivers of immune activation in chronic HIV infection include HIV itself, other co-infecting pathogens, homeostatic responses to cytopenia as well as the recently recognised phenomenon of translocation of microbial products across a damaged gut mucosal surface. This latter process is particularly compelling as clinical studies have shown a good relationship between indices of microbial translocation and markers of both immune activation and T cell homeostasis in chronic HIV infection. More recently, we have also found evidence that these microbial products also may drive a heightened tendency to thrombus formation in HIV infection via induction of monocyte tissue factor expression. Thus systemic exposure to microbial elements that are translocated through a gut mucosa damaged in the first few weeks of HIV infection may contribute to the pathogenesis of both immune deficiency and the heightened risk for vascular events that have been noted in persons with HIV infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694275      PMCID: PMC3394673          DOI: 10.1160/TH10-02-0096

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  49 in total

1.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.

Authors:  Jean-Philippe Herbeuval; Jakob Nilsson; Adriano Boasso; Andrew W Hardy; Michael J Kruhlak; Stephanie A Anderson; Matthew J Dolan; Michel Dy; Jan Andersson; Gene M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses.

Authors:  Priscilla Y Hsue; Peter W Hunt; Elizabeth Sinclair; Barry Bredt; Arlana Franklin; Maudi Killian; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; David D Waters; Steven G Deeks
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

3.  Cardiovascular risks of antiretroviral therapy.

Authors:  James H Stein
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

4.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

5.  HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study.

Authors:  B L Kroner; P S Rosenberg; L M Aledort; W G Alvord; J J Goedert
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-03

6.  Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.

Authors:  Angélique Biancotto; Jean-Charles Grivel; Sarah J Iglehart; Christophe Vanpouille; Andrea Lisco; Scott F Sieg; Robert Debernardo; Kristen Garate; Benigno Rodriguez; Leonid B Margolis; Michael M Lederman
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

7.  Accelerated course of human immunodeficiency virus infection after tuberculosis.

Authors:  C Whalen; C R Horsburgh; D Hom; C Lahart; M Simberkoff; J Ellner
Journal:  Am J Respir Crit Care Med       Date:  1995-01       Impact factor: 21.405

8.  HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes.

Authors:  R Cheynier; S Henrichwark; F Hadida; E Pelletier; E Oksenhendler; B Autran; S Wain-Hobson
Journal:  Cell       Date:  1994-08-12       Impact factor: 41.582

9.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

10.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

View more
  1 in total

1.  Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.

Authors:  Elena Vendrame; Shehnaz K Hussain; Elizabeth Crabb Breen; Larry I Magpantay; Daniel P Widney; Lisa P Jacobson; Daina Variakojis; Emilee R Knowlton; Jay H Bream; Richard F Ambinder; Roger Detels; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.